Advisory Panel

Richard DiMarchi, Ph.D. in Biochemistry Protein Semisynthesis, Biomolecular Sciences

Richard DiMarchi is the Linda & Jack Gill Chair in Biomolecular Sciences, Professor and Chairman of Chemistry at Indiana University. He is a retired Group Vice President at Eli Lilly & Company where for more than two decades he provided leadership in biotechnology, endocrine research and product development. He is a co-founder of Ambrx, Inc. and Marcadia Biotech. He serves as a board member to Ambrx, Marcadia, Isis Pharmaceuticals and the Peptide Therapeutics Foundation. He was co-chairman of the 21st American Peptide Symposium held in Bloomington, Indiana.

Professor DiMarchi is most readily recognized for discovery and development of rDNA-derived Humalog® (LisPro-human insulin). This designer insulin represents the first demonstration that structurally altered rDNA-derived biosynthetic proteins can improve pharmacological performance without increasing the risk of an abnormal immunological response. As scientist and administrator Dr. DiMarchi participated in the commercial development of Humulin®, Humatrope®, Xigris®, Evista®, rGlucagon® and Forteo®.

The goal of his current research and commercial endeavors is to develop proteins with enhanced therapeutic properties through biochemical optimization with non-natural amino acids, an approach termed chemical-biotechnology. He has published more than one hundred papers and he is co-inventor on more than hundred patents. He received the AAPS Career Research Achievement Award in Biotechnology, the ACS Earle B. Barnes Award for Leadership in Chemical Research Management, the ACS Gustavus Esselen Award for Chemistry in the Service of Public Interest, the Wallace Carothers Award for Excellence in Polymer Sciences and the Watanabe Biotechnology-Life Sciences Award.

Philip Dawson, Ph.D. Associate Professor of Cell Biology & Chemistry at the Scripps Research Institute

Philip Dawson is an Associate Professor of Cell Biology and Chemistry at the Scripps Research Institute in La Jolla, CA. He received an A.B. in Chemistry from Washington University in St. Louis in 1992 and a Ph.D. from The Scripps Research Institute in La Jolla, CA where he was a charter member of the graduate program in Macromolecular and Cellular Structure and Chemistry. Following postdoctoral work at the California Institute of Technology, he returned to Scripps to join the faculty. He was elected to the Council of the American Peptide Society and is co-chairman of the 22nd American Peptide Symposium to be held in San Diego, California, 2011. He is on the editorial boards of the International Journal of Peptide Research and Therapeutics, the Journal of Peptide Science, and Biopolymers: Peptide Science, and he is a board member of the Peptide Therapeutics Foundation and the Scientific Advisory board of Solulink Inc.

Professor Dawson is an expert in the area of chemoselective ligation and was an inventor of the widely used native chemical ligation approach for the synthesis and semisynthesis of proteins. His laboratory has developed new approaches for linking unprotected peptides to other biological macromolecules in aqueous solution including the use of mercaptobenzyl ligation auxiliaries and the development of aniline catalysis for oxime and hydrazone ligation reactions. The Dawson lab has used these methods to synthesize a variety of proteins to study protein folding and topology, enzymatic catalysis, homogeneous glycoproteins and domains involved in thrombosis. His current research focuses on the development of new methods for bioconjugation and the efficient synthesis of C-terminally functionalized peptides using both Boc and Fmoc approaches. His laboratory utilizes these methods for the development of HIV vaccine candidates and the application of nanoparticles to biological systems and therapies for lysosomal storage diseases. He has published over 100 papers and reviews and has been honored with the Alfred P. Sloan Foundation fellowship and the du Vigneaud Award from the American Peptide Society.

Chuan Fa Ph.D. Nanyang Technological University in Singapore

Chuan Fa obtained his PhD from the University of Montpellier, France. He did his postdoctoral studies at the Rockefeller University and Vanderbilt University. He joined Amgen in 1996 where he worked with his colleagues on the discovery of peptide-based therapeutics, which has led to the successful development of Amgen's first peptibody drug Nplate. Chuan Fa is now a faculty member of Nanyang Technological University in Singapore.

  • P.O. Box 6153, Fishers, IN 46038
  • Phone: 317-841-7463
  • Toll Free: 800-772-2798
Midwest Bio-Tech, Inc
Midwest Bio-Tech, Inc